Home Novo Nordisk

Novo Nordisk

Stay informed about the latest news about Novo Nordisk by subscribing to our newsletter.

Looking to expand your partner network? Build relationships with academic teams and biotechs.

What is Novo Nordisk best known for?

Novo Nordisk is best known for its expertise in the field of diabetes care. It is a leading global pharmaceutical company specializing in the development, production, and distribution of insulin, as well as other medications and devices for managing diabetes.

Where is Novo Nordisk located?

Novo Nordisk is headquartered in Bagsværd, Denmark. It has a significant presence globally, with operations and offices in various countries, including the United States and many other countries around the world.

Got a news story for us related to Novo Nordisk? Send it to us here.

Latest Posts

Best in Biotech 26 Mar 2024

9 biotech companies leading the way in Denmark

Explore Denmark’s dynamic biotech scene with 9 innovative companies at the forefront of the biopharmaceutical revolution!

March 26, 2024 - 11 minutesmins - By Willow Shah-Neville

In Depth 25 Mar 2024

Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?

Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.

March 25, 2024 - 4 minutesmins - By Willow Shah-Neville

In Depth 27 Feb 2024

Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?

Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition.

February 27, 2024 - 7 minutesmins - By Jules Adam

In Depth 28 Sep 2023

Obesity drug success sparks biotech buying spree

The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […]

September 28, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 13 Apr 2023

Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity

Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […]

April 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Debiopharm adds to oncology pipeline

Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […]

March 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […]

February 10, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Is Copenhagen the world capital of life science?

Denmark’s leading life science companies, public foundations, municipalities, universities and hospitals will work together to position Copenhagen as the world capital of life science through the newly-launched Copenhagen Life Science partnership. Tackling obesity is the first step in this public-private partnership. In 2022, the Danish government invested 82 million DKK ($11.7 million) to strengthen and […]

January 17, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

FDA clears insulin pen medical device

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

More News! 23 Nov 2022

Novo Nordisk announces $750M facility expansion

Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […]

November 23, 2022 - 2 minutesmins - By Jim Cornall

More News! 10 Nov 2022

Novo Nordisk supports Plant2Food platform with €27M funding

Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 4 Oct 2022

ASPIRE set up to collaborate on amyloidosis

A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […]

October 4, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us